NPT 2042

DRUG2 trials

Sponsors

NeuroPro Therapeutics, Inc.

Conditions

EpilepsyEpilepsy, AbsenceEpilepsy, GeneralizedPhotosensitive Epilepsy

Phase 1

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042

CompletedNCT06525649

NeuroPro Therapeutics, Inc.Epilepsy, Photosensitive Epilepsy

Start: 2024-08-21End: 2025-06-26Updated: 2025-07-16

Phase 2

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

RecruitingNCT06769659

NeuroPro Therapeutics, Inc.Epilepsy, Absence, Epilepsy, Generalized

Start: 2025-03-11End: 2026-10-30Target: 12Updated: 2026-05-29